One Ring to rule them all? Flag­ship’s big bet on dom­i­nat­ing gene ther­a­py 2.0 at­tracts a $117M megaround

Over the last 18 months or so, gene ther­a­py has come in for its come­up­pance.

Long known for once-and-done boast­ing, stak­ing claims for cu­ra­tive re­sults on some of the most bit­ter dis­eases known to man, the field has been stag­gered by fail­ure, ev­i­dence of wan­ing ef­fects and fears that ef­fi­ca­cy could wick­er and flame out. And giv­en the ther­a­pies’ vi­ral con­structs, they could on­ly be giv­en once.

As a re­sult, var­i­ous com­pa­nies have been work­ing on dif­fer­ent so­lu­tions. But at Flag­ship, which has been re­think­ing what think­ing big is, there’s one still quite stealthy ef­fort that aims to sweep aside the first gen­er­a­tion of ther­a­pies and sup­plant it with some­thing com­plete­ly new.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER